BiomX Inc. HLSQ
0.53
0.00
0.00%
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow HLSQ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (3.07) | |
P/B ratio |
— | — | — | 0.32 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (0.24) | |
EV/FCF |
— | — | — | (0.24) | |
Quick Ratio |
1.51 | 0.78 | 0.48 | 0.09 | |
Current Ratio |
1.70 | 0.87 | 1.24 | 0.24 | |
Net Debt/EBITDA |
1.08 | 0.30 | 0.90 | (0.14) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 4.77% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.33 | 0.28 | 0.31 | |
Capex/Depreciation |
0.00 | 0.00 | — | (0.40) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 38.55% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,621.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.90 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1,200.90% | |
Graham Net Nets |
— | — | — | (2.27) | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (5,731.33%) | |
Free Cash Flow Yield |
— | — | — | (504.27%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.32 | |
Operating CF per Share |
(43.48) | (26.89) | (20.79) | (1.13) | |
Capex per Share |
(0.01) | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(43.49) | (26.89) | (20.79) | (1.14) | |
Cash per Share |
47.87 | 30.38 | 4.49 | 0.55 | |
Shareholders Equity per Share |
63.47 | (7.98) | (3.38) | 17.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
63.47 | (7.98) | (3.38) | 17.09 | |
Free Cash Flow |
(7.18) | (4.38) | (5.41) | (1.17) | |
Working Capital |
3.64 | (0.80) | 0.60 | (7.76) | |
Capital Expenditures |
0.00 | 0.00 | — | 0.00 | |
Net Current Asset Value |
(6.82) | (1.51) | (1.09) | (8.15) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.01 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (1,136.14%) | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.45 | |
Average Payables |
2.14 | 2.50 | 1.20 | 1.54 | |
Average Assets |
43.07 | 24.51 | 24.45 | 33.12 | |
Average Common Equity |
5.56 | (7.21) | (6.82) | 5.81 |
Columns are period end dates